Meridian Bioscience Obtains FDA Clearance For Legionella Test - Quick Facts

2/27/2012 1:07 PM ET

Meridian Bioscience Inc. (VIVO: Quote) announced that it has received clearance from the U.S. Food and Drug Administration for TRU Legionella, a new rapid assay for detection of legionellosis.

TRU Legionella is a rapid lateral flow device that provides optimized detection of Legionella pneumophila serogroup that is most commonly associated with Legionnaire's disease. Suspected infection is characterized by non-specific upper respiratory symptoms.

Click here to receive FREE breaking news email alerts for Meridian Bioscience Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 179 Articles

Editors Pick

RBNZ Raises OCR To 3.00 Percent

The Reserve Bank of New Zealand on Thursday raised its Official Cash Rate by 25 basis points, to 3.00 percent from 2.75 percent. The decision was in line with expectations, and it marks the second straight month with a rate hike following 24 straight meetings in which the rate was not changed. New Zealand's economic expansion has considerable momentum, with GDP estimated to have grown by 3.5 percent in the year to March.

Apple Profit Climbs 7% On Strong IPhone Sales

Apple Inc. said Wednesday after the markets closed that its second quarter profit rose 7% from last year, as sales surged and margins improved amid strong sales of its iPhones. The company's quarterly earnings per share also came in above analysts' expectations as did its quarterly revenue. At the same time, the company gave a slightly downbeat revenue forecast for the current quarter.

Stocks Give Back Ground Following Recent Upward Trend - U.S. Commentary

Stocks moved mostly lower during trading on Wednesday, giving back some ground after trending higher over the past several sessions. Selling pressure was relatively subdued, however, limiting the downside for the markets. The major averages all closed in the red, although the tech-heavy Nasdaq underperformed its counterparts by a wide margin.